theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Cardiology

Cardiovascular disease   

Questions discussed in this category


Is there any difference in the cardiovascular risk reduction profile of brand name vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
1 Answer available
21917


Papers discussed in this category


The New England journal of medicine, 2019-01-03
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Related Topics in Cardiology

  • Lung Cancer
  • Breast Cancer
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Palliation
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Pediatric Hematology/Oncology
  • Radiation Physics

Copyright © 2025 theMednet
All Rights Reserved.